Conclusion
PRIMARY TUMOR, REFRACTORY MULTIPLE MYELOMA
Our results suggest a marginal benefit by adding cemiplimab to isatuximab, despite demonstration of target engagement, without additional observed safety issues.Preclinical data suggest that concurrent treatment of anti‐CD38 and anti‐PD‐1/PD‐L1 antibodies can substantially reduce primary tumor growth by reversing T‐cell exhaustion, and thus may synergize with anti‐PD‐1/PD‐L1 treatment. This Phase 1/2 trial was designed to determine whether cemiplimab (anti‐PD‐1) enhances the anti‐myeloma activity of isatuximab (anti‐CD38) in patients with relapsed and refractory multiple myeloma, to confirm the feasibility of the combination, determine its efficacy, and further evaluate its safety. We observed a marginal benefit by adding cemiplimab to isatuximab, with target engagement confirmed, and without additional safety issues observed.
